AndroGel vs Jatenzo Side-Effect Profile Head-to-Head

What Are AndroGel and Jatenzo, and Why Does Formulation Matter?

AndroGel and Jatenzo both deliver exogenous testosterone to hypogonadal men, but the delivery mechanism drives most of the differences in side-effect burden. AndroGel absorbs through the skin and enters systemic circulation directly. Jatenzo is absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism, which is why it can be given orally without the liver toxicity seen with older 17-alpha-alkylated oral androgens.

AndroGel: Transdermal Delivery Basics

AndroGel 1% and 1.62% are hydroalcoholic gels applied once daily. Absorption is variable, ranging roughly 9 to 14% of the applied dose depending on skin condition, application site, and bathing habits [1]. The gel dries within minutes but testosterone remains on the skin surface for several hours, which is the direct mechanism behind secondary transfer risk.

The FDA label for AndroGel 1.62% carries a black-box warning specifically about secondary exposure in women and children, citing cases of virilization in pediatric contacts [2]. This is not a theoretical concern. Published case reports describe clitoral enlargement and premature pubic hair in children whose fathers applied gel and did not wash hands or cover the site before contact.

Jatenzo: Oral Lymphatic Absorption

Jatenzo (testosterone undecanoate 158 mg, 198 mg, or 237 mg capsules) must be taken with a meal containing fat. The fat content stimulates chylomicron formation, which carries the lipophilic testosterone undecanoate through intestinal lymphatics into the thoracic duct and then into systemic circulation [3]. Without food, absorption drops sharply and T levels may not reach the therapeutic range.

This absorption mechanism produces a serum T peak roughly 4 to 5 hours post-dose, then a trough before the next dose. Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166) documented that 87% of patients on optimized Jatenzo dosing achieved average serum T concentrations within the normal range (300 to 1,000 ng/dL) at 3 months [3]. Monitoring uses a 6-hour post-dose "Cavg" draw rather than a trough.

Side-Effect Profile: Direct Comparison

Neither drug is free of adverse effects. The side-effect categories differ enough that a man's individual health profile should drive the choice.

Cardiovascular Effects

Jatenzo carries an FDA-mandated warning for blood pressure elevation. In the key trial reported by Swerdloff et al., mean systolic blood pressure increased by approximately 3 to 4 mmHg during the study period [3]. The Jatenzo prescribing information states that the drug is contraindicated in men with uncontrolled hypertension, and the label explicitly warns that it "can increase blood pressure, which can increase the risk of major adverse cardiovascular events (MACE)" [4].

AndroGel does not carry an equivalent BP-specific black-box warning, though testosterone replacement therapy broadly has been associated with cardiovascular risk in older literature. The TRAVERSE trial (N=5,204, mean age 63.3 years), published in the New England Journal of Medicine in 2023, examined transdermal testosterone (primarily gel formulations) in men with hypogonadism and pre-existing or high cardiovascular risk [5]. TRAVERSE found non-inferiority for MACE compared with placebo at a rate of 7.0% vs. 7.3% over a median 33 months, which supports the cardiovascular safety of transdermal testosterone in appropriately selected patients [5].

No equivalent large cardiovascular outcomes trial exists for Jatenzo specifically.

Hematologic Effects: Erythrocytosis and Polycythemia

Both formulations raise hematocrit, because testosterone stimulates erythropoiesis via suppression of hepcidin and direct stimulation of erythroid progenitors [6]. Elevated hematocrit above 54% increases blood viscosity and raises stroke and thrombosis risk.

In the T-Trials (N=790 men aged 65 or older), topical testosterone was associated with a significant increase in hematocrit compared with placebo, with more participants in the testosterone group exceeding hematocrit of 54% (P<0.001) [1]. Jatenzo's prescribing information similarly lists polycythemia as a dose-dependent adverse reaction requiring dose reduction or discontinuation if hematocrit exceeds 54% [4].

Practical implication: both drugs require hematocrit monitoring at 3 to 6 months after initiation and periodically thereafter, per Endocrine Society guidelines [7].

Skin and Application-Site Reactions

AndroGel produces local skin reactions in a meaningful minority of users. The 1.62% label reports application-site reactions (erythema, dryness, burning, irritation) in approximately 3% of trial participants [2]. Men with eczema, psoriasis, or sensitive skin may find these reactions limiting.

Secondary transfer is the more serious skin-related concern. The FDA label states that secondary exposure has resulted in "signs and symptoms of testosterone excess" in female partners and children [2]. Mitigation requires covering the application site with clothing after the gel dries, washing hands immediately, and showering before skin-to-skin contact if possible.

Jatenzo has no application-site reactions. The skin-transfer risk is zero with the oral capsule.

Gastrointestinal Effects

Jatenzo introduces a GI side-effect burden that AndroGel does not. Because each dose must be taken with food, men who skip meals or eat low-fat diets may experience erratic T levels and inadequate symptom control. The key trial reported GI adverse events including diarrhea (3.6%), nausea (2.4%), and abdominal discomfort in a small percentage of patients [3].

AndroGel produces negligible GI effects. This makes AndroGel the simpler choice for men with inflammatory bowel disease, gastroparesis, or those on low-fat diets for cardiac or metabolic reasons.

Hepatic Safety

Jatenzo is not a 17-alpha-alkylated compound, so it does not cause the direct hepatotoxicity associated with older oral androgens such as methyltestosterone [8]. Clinical trials showed no clinically meaningful increases in liver enzymes with Jatenzo at therapeutic doses [3]. AndroGel similarly does not cause hepatotoxicity.

Both drugs can be used in men with mild hepatic impairment, though neither has been studied in severe hepatic impairment and caution is warranted [4].

Dihydrotestosterone Conversion

AndroGel converts to dihydrotestosterone (DHT) in skin via 5-alpha-reductase, and published data show transdermal testosterone raises DHT levels proportionally more than injected testosterone does [9]. Elevated DHT accelerates scalp hair follicle miniaturization in genetically susceptible men and may worsen benign prostatic hyperplasia (BPH) symptoms.

Jatenzo produces more modest DHT elevations relative to the degree of T normalization, because its absorption bypasses the skin where 5-alpha-reductase is most active. Men with significant BPH or androgenic alopecia concerns may prefer Jatenzo for this reason, though the clinical magnitude of the difference requires individual assessment.

Efficacy: How Well Does Each Drug Normalize Testosterone?

T-Trials Evidence for Topical Testosterone

The T-Trials, a coordinated set of seven placebo-controlled trials (N=790 men, aged 65 and older) published in the New England Journal of Medicine in 2016, provided the most comprehensive data on transdermal testosterone outcomes [1]. Topical testosterone (AndroGel 1% and 1.62% were the predominant formulations used) raised serum testosterone from a mean baseline of approximately 234 ng/dL to within the normal range across all seven sub-trials. Sexual function, bone density, and anemia outcomes all showed statistically significant improvement versus placebo [1].

Swerdloff et al. Evidence for Jatenzo

In the phase 3 study by Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166), 87% of men on Jatenzo achieved average serum T in the eugonadal range (300 to 1,000 ng/dL) at 3 months, with a mean Cavg of 456 ng/dL [3]. Dose titration was allowed at weeks 3 and 7. The study excluded men with systolic BP above 150 mmHg at baseline, which is a relevant selection bias when interpreting real-world cardiovascular safety.

Practical Efficacy Considerations

AndroGel's day-to-day T levels can vary based on sweating, bathing timing, and application-site rotation. Jatenzo's T levels vary based on meal composition and timing. Both require monitoring and dose adjustment in a meaningful proportion of patients.

Dosing, Convenience, and Adherence

AndroGel Dosing Schedule

AndroGel 1.62% starts at 40.5 mg (2 pump actuations) applied to shoulders and upper arms each morning. Dose can be titrated to 20.25 mg (minimum) or 81 mg (maximum) based on serum T levels drawn at day 14 and day 28 [2]. Once daily dosing is straightforward. The main adherence barrier is the secondary-transfer precautions, which some men find burdensome, particularly those with young children.

Jatenzo Dosing Schedule

Jatenzo starts at 237 mg twice daily (with morning and evening meals). Dose can be reduced to 158 mg twice daily or increased to 396 mg twice daily based on T monitoring at the 6-hour post-morning-dose point [4]. Twice-daily dosing with food adds complexity. Men who travel frequently, work irregular hours, or routinely skip meals may struggle with consistent adherence.

The table below organizes the head-to-head differences for clinical decision-making:

| Feature | AndroGel 1.62% | Jatenzo | |---|---|---| | Route | Transdermal | Oral (lymphatic) | | Dosing frequency | Once daily | Twice daily with food | | Secondary transfer risk | Yes (black-box warning) | None | | BP elevation warning | No (class-level caution) | Yes (FDA black-box) | | DHT elevation | Pronounced (skin 5-AR) | Modest | | GI adverse effects | Rare | Diarrhea, nausea in ~3 to 4% | | Hepatotoxicity | Not observed | Not observed | | Erythrocytosis risk | Present (monitor Hct) | Present (monitor Hct) | | Monitoring draw timing | Trough (morning, before dose) | 6 hours post-morning dose | | Large CV outcomes trial | TRAVERSE (N=5,204) [5] | None available |

Who Should Avoid Each Drug?

Contraindications for AndroGel

Men with female partners who are pregnant or planning pregnancy should consider the secondary-transfer risk carefully. The FDA notes that fetal harm from androgen exposure is possible [2]. Men with active contact dermatitis, severe seborrheic dermatitis, or skin conditions at the application sites may absorb the drug erratically.

AndroGel is also contraindicated in men with breast cancer or known or suspected prostate cancer, as is all testosterone therapy [7].

Contraindications for Jatenzo

Jatenzo is contraindicated in men with uncontrolled hypertension (generally defined as systolic BP above 150 mmHg) per the prescribing label [4]. Men who have experienced MACE within 6 months, those with heart failure, or those with severe renal impairment should not receive Jatenzo without specialist input.

The requirement for dietary fat also makes Jatenzo impractical for men on very-low-fat therapeutic diets (e.g., post-cholecystectomy fat restriction, severe hypertriglyceridemia managed with extreme dietary fat restriction).

Monitoring Requirements for Each Formulation

Monitoring on AndroGel

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends checking serum T 3 to 6 hours after application at 3 to 6 months after starting therapy, then annually once stable [7]. Hematocrit should be checked at 3 to 6 months, then annually. PSA should be checked at 3 to 6 months, then per age-appropriate prostate cancer screening guidelines.

"We suggest that clinicians check testosterone levels 3 to 6 months after initiating therapy," states the Endocrine Society 2018 guideline, with monitoring targeted to the midpoint of the normal male range (400 to 700 ng/dL as a practical target) [7].

Monitoring on Jatenzo

Jatenzo monitoring requires a serum T draw exactly 6 hours after the morning dose, because this approximates the average daily concentration (Cavg) used in clinical trials [4]. Standard trough or peak draws are not informative for this formulation. Blood pressure should be measured at every clinic visit given the BP-elevation warning. Hematocrit and PSA schedules mirror AndroGel.

Cost, Insurance Coverage, and Access

AndroGel has been available since 2000 and generic testosterone gel (1%) is widely available at substantially lower cost. GoodRx pricing for generic testosterone gel 1% runs approximately $30 to 60 per month at major pharmacies, depending on dose and region.

Jatenzo received FDA approval in March 2019 and remains brand-only as of early 2025 [4]. List price runs considerably higher, and insurance formulary placement varies. Prior authorization is common for Jatenzo given its brand status and the availability of cheaper alternatives.

Men paying out of pocket should confirm current formulary status with their insurer, as Jatenzo's cost differential relative to generic gel is significant and may affect long-term adherence.